Zura Bio Names Immunology Veteran Sandeep Kulkarni as CEO Amid Critical Clinical Readouts
Event summary
- Sandeep Kulkarni, M.D., appointed CEO of Zura Bio effective January 21, 2026, replacing Robert Lisicki, who resigns as CEO and Director.
- Kulkarni brings over 20 years of experience in biotechnology, investment, and medicine, most recently as co-founder and CEO of Tourmaline Bio, acquired by Novartis in October 2025.
- Zura Bio's lead program, tibulizumab, is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways, with Phase 2 trials in hidradenitis suppurativa and systemic sclerosis.
- Two potentially transformative clinical readouts expected within the next 18 months.
- Kim Davis continues as Chief Operating Officer, Chief Legal Officer, and Corporate Secretary.
The big picture
Zura Bio's appointment of Sandeep Kulkarni as CEO comes at a pivotal time, with two critical clinical readouts on the horizon. Kulkarni's background in biotech entrepreneurship and investment suggests a strategic focus on scaling the company's innovative pipeline. The move underscores the importance of leadership continuity in navigating the complex landscape of autoimmune disease treatments, where differentiation and clinical success are key to securing market position and investor confidence.
What we're watching
- Clinical Milestones
- How the upcoming Phase 2 readouts for tibulizumab will validate Zura Bio's dual-pathway antibody approach and position it in the competitive autoimmune disease market.
- Leadership Impact
- Whether Sandeep Kulkarni's strategic and operational experience can accelerate Zura Bio's development pipeline and secure additional funding or partnerships.
- Market Differentiation
- The pace at which Zura Bio can differentiate tibulizumab from existing therapies and establish its lead in the bispecific antibody space for autoimmune diseases.
Our editorial coverage:
Related topics